Drug Profile
Research programme: bleeding therapeutics (Ebola virus) - Fibreu Limited
Latest Information Update: 22 Sep 2023
Price :
$50
*
At a glance
- Originator Fibreu
- Class Acute-phase proteins; Antihaemorrhagics; Blood coagulation factors; Coagulants
- Mechanism of Action Fibrinogen replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Haemorrhage
Most Recent Events
- 22 Sep 2023 Discontinued - Preclinical for Haemorrhage in United Kingdom (unspecified route)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Haemorrhage in United Kingdom
- 10 Aug 2016 Preclinical trials in Haemorrhage in United Kingdom (unspecified route)